替吉奥对比卡培他滨在晚期乳腺癌疗效及安全性的Meta分析

Meta-analysis of the Efficacy and Safety of Tiggio Versus Capecitabine in Advanced Breast Cancer

目的对替吉奥与卡培他滨在晚期乳腺癌的疗效及安全性进行Meta分析。方法计算机检索Pubmed、The Cochrane Library、EMbase、CKNI、万方数据库,按照纳入和排除标准筛选文献和提取资料后,采用RevMan 5.3软件进行Meta分析。结果最终纳入12篇文献,包括829例患者。Meta分析结果显示,替吉奥较卡培他滨能有效改善晚期乳腺癌疾病控制率,差异有统计学意义[OR=1.64(1.12,2.40),P=0.01];而二者客观缓解率比较,差异无统计学意义[OR=1.34(0.99,1.81),P=0.05];安全性方面:替吉奥在恶性呕吐[OR=0.32(0.16,0.65),P=0.002]、手足综合症[OR=0.14(0.06,0.30),P<0.00001]发生率低于卡培他滨,差异有统计学意义。结论在治疗晚期乳腺癌方面,替吉奥与卡培他滨相比能有效改善疾病控制率,在恶性呕吐及手足综合症方面具有更良好的安全性。

Objective To conduct a meta-analysis of the efficacy and safety of Tiggio and capecitabine in advanced breast cancer. Methods The Pubmed, The Cochrane Library, EMbase, CKNI, and Wanfang databases were searched by computer. After screening and extracting data according to inclusion and exclusion criteria, meta-analysis was performed using RevMan 5.3 software. Results A total of 12 articles were included, including 829 patients. Meta-analysis showed that Tiggio was more effective than capecitabine in improving the control rate of advanced breast cancer, and the difference was statistically significant [OR=1.64 (1.12, 2.40), P=0.01];The difference was not statistically significant [OR=1.34 (0.99, 1.81), P=0.05];safety: Tiggio in malignant vomiting [OR=0.32 (0.16, 0.65), P=0.002], hand-foot syndrome [ The incidence of OR=0.14 (0.06, 0.30), P<0.00001] was lower than that of capecitabine, and the difference was statistically significant. Conclusion In the treatment of advanced breast cancer, tiggio can effectively improve the disease control rate compared with capecitabine, and has better safety in malignant vomiting and hand-foot syndrome.